Letters DPP-4 inhibitors for type 2 diabetes

Authors’ reply to Scheffel and Schaan

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2922 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2922
  1. Apostolos Tsapas, assistant professor1,
  2. Thomas Karagiannis, research fellow1,
  3. Paschalis Paschos, research fellow1,
  4. Konstantinos Paletas, professor1,
  5. David R Matthews, professor in diabetic medicine2
  1. 1Aristotle University Thessaloniki, 54642, Thessaloniki, Greece
  2. 2Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
  1. atsapas{at}auth.gr

We appreciate Scheffel and Schaan’s response to our systematic review.1 2 Our meta-analysis provides evidence that dipeptidyl peptidase-4 (DPP-4) inhibitors are indeed inferior to metformin and GLP-1 agonists on the primary endpoint of change in glycated haemoglobin (HbA1c). However, we do not agree with their interpretation of …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe